Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
NASDAQ:PTIX

Atrinsic 9/10/2025 Earnings Report

Atrinsic logo
$0.65 0.00 (0.00%)
As of 01:10 PM Eastern
ProfileEarnings HistoryForecast

Atrinsic EPS Results

Actual EPS
-$1.37
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Atrinsic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atrinsic Announcement Details

Quarter
Date
9/10/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Atrinsic Earnings Headlines

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
July 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/30/3124067/0/en/protagenic-therapeutics-announces-grant-of-new-patent-in-japan-for-its-modified-stilbenoid-program-drug-candidates.html
Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance
June 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PTIX/news/
The smartest SpaceX play before Memorial Day
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, supplier Broadcom gained 15,000%. The pattern is clear: suppliers often dwarf the headline stock. One little-known company has shipped over 5 billion chips to SpaceX - a figure expected to reach 10 billion by 2027. SpaceX calls them 'instrumental to Starlink's success.' With the IPO expected in June, you can get the name, ticker, and a full year of tech research for just $19 - 85% off.tc pixel
May 18 at 1:00 AM  |  Weiss Ratings (Ad)
Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy
May 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/protagenic-phytanix-merge-in-all-stock-move-sparking-retail-frenzy/ar-AA1FJicU
Protagenic Therapeutics swaps warrants for shares
May 21, 2025  |  uk.investing.comhttps://uk.investing.com/news/sec-filings/protagenic-therapeutics-swaps-warrants-for-shares-93CH-4095880
Protagenic Therapeutics Shares Double After Buyout Offer From Phytanix Bio
May 20, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/protagenic-therapeutics-shares-double-after-buyout-offer-from-phytanix-bio-4ee93d1e
See More Atrinsic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atrinsic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrinsic and other key companies, straight to your email.

About Atrinsic

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

View Atrinsic Profile
Earnings Tools